{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004419","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.768133+00:00","generated_at":"2026-06-26T19:38:13.947936+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aura Biosciences reports FY2021 net loss $35.3M; cash $149.1M into 2024","bullets":["Net loss for FY2021 was $35.3M, up from $22.2M in FY2020; R&D expenses rose to $25.2M.","Cash and equivalents totaled $149.1M at Dec 31, 2021; runway into 2024.","On track to initiate pivotal trial in choroidal melanoma and Phase 1 in NMIBC in 2H 2022.","European Commission granted Orphan Drug Designation for AU-011 in uveal melanoma.","John Maraganore, former Alnylam CEO, joins as strategic advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004419","json":"https://secwatch.observer/filing/0000950170-22-004419.json","markdown":"https://secwatch.observer/filing/0000950170-22-004419.md","text":"https://secwatch.observer/filing/0000950170-22-004419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022004419/0000950170-22-004419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022004419/aura-20220323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T19:38:13.947936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}